Abstract:
The present invention relates to a method for preparing monoglyceride sulfonate that is useful for a cleansing agent for a human body, economically in a large amount, from an inexpensive fatty acid using a convenient manufacturing unit. The present invention also provides a soft soap composition comprising monoglyceride sulfonate and a fatty acid soap, which has superior molding and stamping workability, softness, smoothness, foamability, and moisturizing ability. The present invention also provides a method for preparing a salt-containing soft soap using the fatty acid used for preparation of the monoglyceride sulfonate, which contains a lot of salt, so that is softens skin, easily removes waste materials, prevents irritation, promotes blood circulation, and prevents depilation and dandruff.
Abstract:
Methods and therapeutic compounds for treating pain, mitigating inflammation, effecting analgesia and/or effecting sedation in a subject are described. A subject is administered an effective amount of a therapeutic compound which is a nitrate ester. Novel pharmaceutical compositions are also described.
Abstract:
Methods and therapeutic compounds for treating pain, mitigating inflammation, effecting analgesia and/or effecting sedation in a subject are described. A subject is administered an effective amount of a therapeutic compound which is a nitrate ester. Novel pharmaceutical compositions are also described.
Abstract:
Blends of N-acyl aminoalkane sulfonates and amphoteric and/or anionic surfactants can be prepared by quenching a molten reaction mixture of an aminoalkane sulfonate amidated with a fatty acid with an aqueous solution comprising an amphoteric and/or anionic surfactant. N-acyl aminoalkane sulfonates can be purified by quenching a molten reaction mixture in isopropanol.
Abstract:
Isethionate esters of alkyl carboxylic acids of formula (I) where R is a substituted or unsubstituted C8 to C24 alkyl or alkenyl group, m is 1 to 3 and n is 1 to 8 are mild surfactants and have good foaming properties. They can be incorporated into a wide range of personal care e.g. body and facial cleansing composition and detergent compositions.
Abstract:
Die Erfindung betrifft eine Zusammensetzung umfassend ein fluorhaltiges Tensid mit einer kationischen Gruppe, einer divalenten schwefelhaltigen Gruppe und einer fluorierten Gruppe, sowie ferner umfassend ein zu der kationischen Gruppe des fluorhaltigen Tensids korrespondierendes Anion, wobei es sich bei der kationischen Gruppe um eine N-alkylierte heterozyklische Gruppe handelt.
Abstract:
A surfactant represented by the formula R1COOC(C)nCR2OR3 wherein: R1 is CH3(CH2)m and may be interrupted with at least one heteroatom selected from the group consisting of amine, ether, ester, amide, sulfur, sulfur monoxide, sulfer dioxide, sulfamate, hydroxy, or mixtures thereof; and m = 6-16; n = 0 or 1; R2 = H or CH3; and R3 = H, SO3X, CO(CH)2COOH, or COCH(S03X)CH2COOX1; wherein X and X1 are the same or different, and each is selected from NH4+, an alkali metal, or an H atom.
Abstract translation:由式R 1 COCO(C)n CR 2 OR 3表示的表面活性剂,其中:R 1是CH 3(CH 2)m,并且可以被至少一个选自胺,醚,酯,酰胺,硫,一氧化硫,二氧化硫 ,氨基磺酸盐,羟基或其混合物; m = 6-16; n = 0或1; R2 = H或CH3; 和R3 = H,SO3X,CO(CH)2COOH或COCH(SO3X)CH2COOX1; 其中X和X 1相同或不同,并且各自选自NH 4 +,碱金属或H原子。
Abstract:
A pattern forming method, includes: (i) forming a film from an actinic ray-sensitive or radiation-sensitive resin composition that contains (A) a compound capable of generating an acid upon irradiation with an actinic ray or radiation and decomposing by an action of an acid to decrease a solubility of the compound (A) for an organic solvent; (ii) exposing the film; and (iii) performing development by using a developer containing an organic solvent.
Abstract:
The invention pertains to a compound generating an acid of the formula (I) or (II), for instance corresponding sulfonium and iodonium salts, as well as corresponding sulfonyloximes, Formula (I) and Formula (II), wherein X is CH 2 or CO; Y is O, NR 4 , S, O(CO), O(CO)O, O(CO)NR 4 , OSO 2 , O(CS), or O(CS)NR 4 ; R 1 is for example C 1 -C 18 alkyl, C 1 -C 10 haloalkyl, C 2 -C 12 alkenyl, C 4 -C 30 cycloalkenyl, phenyl-C 1 -C 3 -alkyl, C 3 -C 30 cycloalkyl, C 3 -C 30 cycloalkyl-C 1 -C 18 alkyl, interrupted C 2 -C 18 alkyl, interrupted C 3 -C 30 cycloalkyl, interrupted C 3 -C 30 cycloalkyl-C 1 -C 18 alkyl, interrupted C 4 -C 30 cycloalkenyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or heteroaryl, all unsubstituted or are substituted; or R 1 is NR 12 R 13 ; R 2 and R 3 are for example C 3 -C 30 cycloalkylene, C 3 -C 30 cycloalkyl-C 1 -C 18 alkylene, C 1 -C 18 alkylene, C 1 -C 10 haloalkylene, C 2 -C 12 alkenylene, C 4 -C 30 cycloalkenylene, phenylene, naphthylene, anthracylene, phenanthrylene, biphenylene or heteroarylene; all unsubstituted or substituted; R 4 is for example C 3 -C 30 cycloalkyl, C 3 -C 30 cycloalkyl-C 1 -C 18 alkyl, C 1 -C 18 alkyl, C 1 -C 10 haloalkyl, C 2 -C 12 alkenyl, C 4 -C 30 cycloalkenyl, phenyl-C 1 -C 3 -alkyl; R 12 and R 13 are for example C 3 -C 30 cycloalkyl, C 3 -C 30 cycloalkyl-C 1 -C 18 alkyl, C 1 -C 18 alkyl, C 1 -C 10 haloalkyl, C 2 -C 12 alkenyl, C 4 -C 30 cycloalkenyl, phenyl-C 1 -C 3 -alkyl, Ar, (CO)R 15 , (CO)OR 15 or SO 2 R 15 ; and Ar is phenyl, biphenylyl, fluorenyl, naphthyl, anthracyl, phenanthryl or heteroaryl, all unsubstituted or substituted.